Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells

Abboud, E. R., Coffelt, S. B. , Figueroa, Y. G., Zwezdaryk, K. J., Nelson, A. B., Sullivan, D. E., Morris, C. B., Tang, Y., Beckman, B. S. and Scandurro, A. B. (2007) Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells. International Journal of Oncology, 30(1), pp. 113-122. (doi:10.3892/ijo.30.1.113) (PMID:17143519)

Full text not currently available from Enlighten.

Abstract

Based on cDNA microarray results, integrin-linked kinase (ILK) emerged as an interesting candidate in hypoxia-mediated survival mechanisms employed by cancer cells. This notion was confirmed here by the following observations: the 5' promoter region of the ilk gene contains hypoxia responsive elements (HRE) that bind hypoxia-inducible factor (HIF) transcription factor complexes and drive HRE-luciferase gene expression in reporter assays; ILK protein and kinase activity are induced following hypoxia; downstream targets of ILK signaling are induced following hypoxia treatment; inhibition of ILK leads to increased apoptosis; and HIF and ILK are co-localized within human cancer tissues. The identification of ILK as a player in hypoxia survival signaling employed by cancer cells further validates ILK as a unique target for cancer therapy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Coffelt, Dr Seth
Authors: Abboud, E. R., Coffelt, S. B., Figueroa, Y. G., Zwezdaryk, K. J., Nelson, A. B., Sullivan, D. E., Morris, C. B., Tang, Y., Beckman, B. S., and Scandurro, A. B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:International Journal of Oncology
Publisher:Spandidos Publications
ISSN:1019-6439
ISSN (Online):1791-2423
Published Online:01 January 2007

University Staff: Request a correction | Enlighten Editors: Update this record